Yellow fever is an acute viral haemorrhagic disease spread through mosquito bites. Reported cases of yellow fever have increased to 2064 in 2018 from 876 in 2017 which is more than double in number across the globe. Yellow fever originated in Africa and more than 30 countries in Africa have reported yellow fever cases. There is no specific anti-viral drug for yellow fever. However, yellow fever vaccine is available, and a single dose of vaccine can provide a life-long protection against the disease. In September 2019, Federal Government collaboration with WHO, Vaccine Alliance and Gavi, launched yellow fever reactive vaccination campaign which target about 1.6 million people in Nigeria. In 2019, Sanofi Pasteur was given FDA license for expanding production facility for manufacturing YF-VAX i.e. yellow fever vaccine. This will assist in availability of yellow fever vaccine in U.S. through expanded access Investigational New Drug Application (IND). The sale of YF-VAX will be post 2020 till then STAMARIL will be sold in US for providing protection against yellow fever virus. YF-VAX (Sanofi Pasteur, Inc), STAMARIL (Sanofi Pasteur, Inc) are the common brands

Rising prevalence of yellow fever, improving healthcare infrastructure, and favorable government policies are the major factor supporting the growth of the yellow fever market.

Some of the key players operating in the market are Sanofi, Bio-Manguinhos, Institut Pasteur de Dakar and iBio among others.

To gather deep-rooted insights with respect to market dynamics, competitive landscape and to unlock the market potential of yellow fever vaccine, subscribe to the report by clicking and filling up the ‘Pre-book’ section.